Liraglutide for MODY diabetes treatment study
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether liraglutide, a once-daily injection, helps manage blood sugar in people with MODY diabetes. It's for those with high A1c levels and no prior use of similar drugs or certain health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of MODY diabetes.
- Your A1c must be above 6.5% but not higher than 10%.
- You cannot have had an allergic reaction to GLP-1 drugs like liraglutide before.
- You must not be taking any GLP-1 drugs or stimulant medications currently.
- You should have no history of certain cancers (especially medullary thyroid cancer), pancreatitis, or severe kidney disease.
- You cannot be pregnant, have had bariatric surgery, or have very low body weight.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication (called a GLP-1 receptor agonist) to see if it can help people in the earliest stage of type 1 diabetes keep their insulin-making cells working longer. It might help delay the need for insulin injections.
This trial tests an experimental pill (a glucokinase activator) in adults with a specific genetic form of diabetes called GCK-MODY. The study aims to see if the pill can help control blood sugar without causing dangerously low sugar levels.
This trial compares two treatment approaches—liraglutide injections versus a specific insulin (glargine) injection—plus meal-time insulin dosing (“bolus”) in adults with overweight/obesity and type 2 diabetes that isn’t well controlled. The goal is to see which option works better and is safer for improving blood sugar.
This trial tests if a weekly injection of dulaglutide (Trulicity) can help children with type 2 diabetes control their blood sugar when used together with metformin and/or insulin. It may be an option for kids who are overweight.
This study looks at how blood sugar control and a class of drugs called GLP-1 agonists (like Ozempic) affect insulin-making cells in people with type 1 or type 2 diabetes who use insulin.
This study tests if adding a non-insulin medication can lower the amount of insulin needed while improving heart and metabolic health in people with type 1 diabetes. It may also help understand how this approach works in people with a genetic form of diabetes (GCK-MODY).
Hear when a new Maturity Onset Diabetes of the Young trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.